{"disease":{"id":"malignant-advanced-solid-tumor","name":"malignant advanced solid tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07307053","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04495790","title":"AIMS Cancer Outcomes Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Advanced Integrative Medical Science Institute","has_results":false},{"nct_id":"NCT05245500","title":"Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05094804","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT06090266","title":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT05495295","title":"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":149,"lead_sponsor_name":"Phost'In Therapeutics","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06566079","title":"Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"InSilico Medicine Hong Kong Limited","has_results":false},{"nct_id":"NCT06209580","title":"AMT-253 in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Multitude Therapeutics Inc.","has_results":false},{"nct_id":"NCT05082610","title":"A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Hummingbird Bioscience","has_results":false},{"nct_id":"NCT05169437","title":"Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Tempus AI","has_results":true},{"nct_id":"NCT06912152","title":"MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07378436","title":"A Clinical Study of GK02 in Malignant Ascites","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Beijing Geekgene Technology Co., LTD","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}